This article is for general information only and should not be treated as tax, legal or professional advice. Tax law changes frequently and the application of any rule depends on the specific circumstances of each taxpayer. Professional advice should be obtained before acting on the information in this article.
Introduction
Cyprus has long provided tax deductions for expenditure incurred on scientific research and research and development activities.
A specific additional deduction equal to 20% of qualifying R&D expenditure was introduced in 2022 and has subsequently been extended. Following the 2026 Cyprus tax reform, the additional deduction is available, subject to the applicable conditions, for qualifying expenditure through 31 December 2030.
For Cyprus businesses investing in genuine research and development — including technology, software, pharmaceuticals, engineering and other innovative activities — the incentive can provide an additional tax benefit.
Where qualifying R&D expenditure is otherwise deductible in full, the taxpayer may effectively obtain a tax deduction of 120% of the qualifying expenditure: the normal 100% deduction plus an additional 20%.
At the current Cyprus corporate income tax rate of 15%, the additional 20% deduction can produce an incremental tax benefit of up to 3% of the qualifying expenditure, depending on the taxpayer’s tax position and the timing and utilisation of the deduction.
However, the Cyprus R&D incentive is subject to specific conditions. In particular, the legislation refers to scientific research and R&D expenditure recognised under applicable international accounting standards and requires consideration of the taxpayer’s business activities and economic ownership of any intangible asset arising, or potentially arising, from the R&D.
There is also an important restriction where the Cyprus IP Box applies to the same qualifying intangible asset.
This guide explains how the Cyprus R&D super-deduction works, which businesses may fall within its scope, the types of expenditure that should be considered, and its interaction with the Cyprus IP Box regime.
What Is the Cyprus R&D Super-Deduction?
The Cyprus R&D super-deduction provides an additional deduction equal to 20% of qualifying scientific research and R&D expenditure.
Where the underlying expenditure is fully deductible in the relevant year, this may result in a total tax deduction equal to 120% of the qualifying expenditure.
The additional 20% is not a tax credit, and it is not cash received from the government. It is an additional deduction when calculating taxable income.
A simple illustration
Assume a Cyprus company incurs €500,000 of qualifying R&D expenditure which is fully deductible in 2026.
Under the ordinary tax rules, a €500,000 deduction would reduce the company’s corporate income tax liability by up to:
€500,000 × 15% = €75,000
With the additional 20% R&D deduction, the total deduction would be:
€500,000 × 120% = €600,000
The corresponding tax reduction, assuming sufficient taxable profits, would be:
€600,000 × 15% = €90,000
The incremental tax benefit arising from the additional R&D deduction is therefore:
€100,000 × 15% = €15,000
This represents an additional tax benefit equal to 3% of the qualifying R&D expenditure.
For businesses with larger qualifying R&D budgets, the absolute benefit can become significant.
The actual timing of the benefit may differ where expenditure is capitalised rather than deducted immediately.
Who May Be Eligible for the Deduction?
The legislation is not limited exclusively to a particular industry or to large companies.
The relevant provisions apply in the context of taxpayers carrying on a business and incurring qualifying scientific research or R&D expenditure. Cyprus tax-resident companies will therefore commonly fall within the scope, while other taxpayers subject to Cyprus tax on business profits, including certain permanent establishments, require consideration based on their specific circumstances.
Businesses that may potentially incur qualifying expenditure include:
- Technology companies developing new or significantly improved software, platforms, systems or technological solutions
- Software development businesses carrying out genuine development activities rather than routine coding or maintenance
- Pharmaceutical and life sciences businesses undertaking qualifying research and development
- Engineering and manufacturing businesses developing new products, processes or technological solutions
- Businesses developing proprietary intellectual property, including software, patents and other intangible assets
- Other innovative businesses undertaking activities that meet the relevant accounting and tax requirements for research and development
The nature of the activity is more important than the industry in which the business operates.
Importantly, Cyprus tax legislation should not be approached solely by applying R&D tests developed for tax regimes in other jurisdictions.
The analysis should consider whether the expenditure relates to scientific research or research and development as recognised under the applicable international accounting standards, together with the other requirements of Cyprus tax legislation.
What Expenditure May Qualify?
The legislation should not be interpreted as providing a simple statutory checklist of qualifying cost categories.
Instead, the starting point is whether the expenditure relates to qualifying scientific research or R&D activities recognised under the relevant accounting framework and satisfies the requirements of the Cyprus Income Tax Law.
Depending on the circumstances, expenditure requiring consideration may include the following.
Staff costs directly attributable to R&D
Salaries, wages and employer-related employment costs attributable to employees working directly on qualifying R&D activities may potentially fall within the relevant expenditure.
Where employees divide their time between R&D and other activities, an appropriate and supportable allocation should be maintained.
Time records or other contemporaneous evidence can therefore be important in supporting the calculation.
Externally commissioned R&D
Expenditure paid to third-party researchers, technical specialists, universities, consultants or other organisations may require consideration where the work forms part of the taxpayer’s qualifying R&D activities.
Particular attention should be given to contractual arrangements and to whether the taxpayer has the required economic ownership of the intangible asset that arises or may arise from the R&D activities.
Development of intangible assets
Qualifying development activity may result in the creation of software, patents, proprietary technology or other intangible assets.
The accounting treatment of such expenditure is important.
Under the applicable accounting standards, certain research expenditure is generally expensed, whereas development expenditure may be capitalised where the relevant recognition criteria are satisfied.
Where expenditure is capitalised for tax purposes, the tax deduction may arise over a number of years rather than being available entirely in the year in which the cost is incurred.
Accordingly, businesses should not automatically assume that all R&D expenditure results in an immediate 120% deduction.
What Generally Does Not Qualify?
Not every expenditure connected with developing a business, product or technology will constitute qualifying R&D expenditure.
Examples of costs or activities that would generally require exclusion or separate consideration include:
- Routine product updates or ordinary commercial development that does not constitute research or development under the applicable accounting framework
- Routine software coding, maintenance and bug fixing where these activities do not form part of qualifying development
- Marketing research, customer surveys and product-market testing
- Sales, marketing and commercialisation expenditure
- General administrative expenditure that cannot be appropriately attributed to qualifying R&D activities
- Tangible capital expenditure on buildings, machinery, installations or similar assets where separate tax depreciation or capital allowance provisions apply
- Expenditure incurred after the relevant R&D or development activities have ended, including ordinary commercial exploitation of the completed product
The classification of expenditure should ultimately be based on the facts, the applicable accounting treatment and the Cyprus tax legislation.
Accounting Treatment Is Important
One of the areas that can easily be overlooked when assessing the Cyprus R&D incentive is the interaction between the tax legislation and the applicable international accounting standards.
The legislation refers specifically to scientific research and R&D expenditure recognised under international accounting standards.
For businesses reporting under IFRS, IAS 38 — Intangible Assets is particularly relevant when distinguishing between research expenditure and development expenditure and determining whether development costs should be expensed or capitalised.
This distinction can affect the timing of the tax deduction.
Where qualifying expenditure is deductible as a revenue expense, the ordinary deduction and additional R&D deduction may generally arise in the relevant tax year.
Where qualifying development expenditure is capitalised as an intangible asset and falls within the relevant Cyprus tax provisions for capital expenditure on intangible assets, the tax deduction may instead be spread over the applicable useful economic life.
The additional R&D deduction should therefore be considered together with the tax treatment of the underlying expenditure rather than as an entirely separate year-one deduction.
How the Deduction Works in Practice
The qualifying R&D deduction forms part of the taxpayer’s Cyprus income tax computation.
The additional 20% deduction reduces taxable income and may therefore:
- reduce an existing taxable profit;
- eliminate taxable profit for the year;
- contribute to the creation of a tax loss; or
- increase an existing tax loss.
This is important for early-stage technology companies and other R&D-intensive businesses that may not yet be profitable.
Loss-making R&D businesses
A loss-making business will generally obtain no immediate cash-tax benefit from an additional deduction because it does not have taxable profits against which the deduction can be utilised in that year.
However, the deduction may increase the company’s tax loss.
Under the rules applicable following the 2026 Cyprus tax reform, qualifying tax losses may generally be carried forward for up to seven years, subject to the normal Cyprus tax-loss provisions and applicable restrictions.
The R&D deduction may therefore still provide value to a business that expects to become profitable in future years.
Documentation and Supporting Evidence
A robust R&D tax position should be supported by contemporaneous documentation.
Although the Cyprus legislation does not prescribe a single standard R&D claim file applicable to every taxpayer, businesses should consider maintaining documentation including:
- A description of each significant research or development project
- The purpose and nature of the R&D activities performed
- An analysis of why the activities constitute research or development under the relevant accounting framework
- Accounting documentation supporting the classification of research and development expenditure
- Staff allocation or time records supporting directly attributable employment costs
- Supplier invoices and contracts relating to outsourced or commissioned R&D
- Documentation concerning ownership and economic rights over intellectual property arising from the activities
- A reconciliation between the qualifying expenditure, accounting records and corporate income tax computation
- Evidence supporting the treatment of any capitalised development expenditure
Documentation should ideally be created as the project progresses rather than reconstructed only when the tax return is prepared.
This is particularly important for companies with mixed activities where employees and external contractors work on both qualifying and non-qualifying projects.
Interaction With the Cyprus IP Box
Cyprus also operates an intellectual property regime commonly referred to as the Cyprus IP Box.
Subject to its conditions, the IP Box provides an 80% exemption on qualifying profits derived from qualifying intangible assets.
At the current 15% corporate income tax rate, this can result in an effective tax rate of as low as 3% on qualifying IP profits before considering other aspects of the tax computation.
The IP Box operates under the OECD nexus approach, under which the proportion of qualifying IP profits benefiting from the regime is linked to qualifying expenditure incurred in developing the relevant intellectual property.
Important restriction on combining the regimes
Businesses should not assume that the additional 20% R&D deduction and the Cyprus IP Box can simply be applied to different stages of the same intangible asset.
The Cyprus R&D provisions restrict the additional 20% deduction where the expenditure relates to a qualifying intangible asset in respect of which the Cyprus IP Box provisions have applied in any tax year, including the current year.
Accordingly, where a business develops intellectual property that may subsequently fall within the Cyprus IP Box, the interaction between the two incentives should be considered before claims are made.
The appropriate treatment may depend on:
- the particular intangible asset;
- the expenditure attributable to that asset;
- whether the IP Box provisions have applied to that asset;
- the timing of the relevant deductions and income; and
- the ownership and development arrangements.
This does not necessarily prevent a taxpayer from having different projects or intangible assets benefiting from different tax provisions.
However, the additional 20% R&D deduction should not be presented as automatically available for the development expenditure of the same qualifying intangible asset that benefits from the IP Box.
A project-by-project and asset-by-asset analysis is advisable.
The 2026 Reform: What Changed?
The Cyprus tax reform applying from 1 January 2026 made several significant changes to the corporate tax framework.
Among these changes, the availability of the additional 20% R&D deduction was extended through 31 December 2030.
The standard Cyprus corporate income tax rate also increased from 12.5% to 15%.
As a result, where an additional R&D deduction is available and can be utilised, its absolute tax value is higher than under the previous 12.5% corporate income tax rate.
For example:
- At 12.5%, an additional 20% deduction produced an incremental benefit of up to 2.5% of qualifying expenditure
- At 15%, the same additional deduction produces an incremental benefit of up to 3% of qualifying expenditure
The corporate tax rate increase forms part of the wider Cyprus tax reform and should be viewed in the broader context of changes to Cyprus’s domestic and international tax framework.
It should not be confused with the separate OECD Pillar Two regime, which applies its own global minimum tax rules to large multinational and domestic groups meeting the relevant revenue threshold.
Frequently Asked Questions
1. Does software development qualify for the 120% R&D deduction?
Potentially. However, not all software development constitutes qualifying R&D. The assessment should consider the nature of the development activities, the applicable accounting treatment and whether the expenditure constitutes research or development within the relevant accounting framework and satisfies the Cyprus tax requirements.
Routine coding, ordinary maintenance, straightforward feature additions, interface changes and bug fixes should not automatically be treated as qualifying R&D expenditure. Each significant development project should be analysed separately.
2. Can a startup claim the R&D super-deduction if it is loss-making?
Potentially, yes. The absence of taxable profits does not necessarily prevent the deduction from being recognised in the tax computation. The deduction may contribute to or increase a tax loss.
Such losses may generally be carried forward for up to seven years under the rules applying following the 2026 tax reform, subject to the usual Cyprus tax-loss conditions and restrictions. The economic value of the relief will therefore depend on whether and when the business generates sufficient taxable profits to utilise those losses.
3. Can we claim the R&D super-deduction and the IP Box on the same project?
This requires particular care. The additional 20% R&D deduction is restricted where the relevant expenditure relates to a qualifying intangible asset in respect of which the Cyprus IP Box provisions have applied in any year, including the current year.
Businesses considering both regimes should therefore perform an asset-specific analysis before applying either incentive. Different intangible assets or projects within the same company may potentially have different tax treatments.
4. What records should we keep?
Businesses should maintain sufficient evidence to demonstrate:
- what research and development activity was undertaken;
- the accounting treatment applied;
- how the qualifying expenditure was identified and calculated;
- which employees and external suppliers were involved;
- how expenditure was allocated between qualifying and non-qualifying activities;
- who has economic ownership of any resulting intellectual property; and
- how the tax deduction reconciles to the company’s accounting records.
Contemporaneous documentation is preferable to attempting to reconstruct the analysis after the end of the tax year.
5. Is the deduction available to non-resident companies with a Cyprus permanent establishment?
Potentially, depending on the circumstances. The R&D provisions are not drafted solely by reference to Cyprus tax-resident companies. A non-resident entity carrying on business through a Cyprus permanent establishment may therefore require consideration where the relevant income and expenditure are attributable to the Cyprus PE. The precise treatment should be assessed based on the activities, ownership arrangements and applicable Cyprus tax provisions.
6. When does the R&D super-deduction expire?
Under the legislation currently in force, the additional 20% deduction applies to qualifying expenditure through 31 December 2030. Expenditure incurred after that date would not benefit from the additional deduction unless the incentive is extended again through subsequent legislation.
Practical Considerations Before Making a Claim
The Cyprus R&D incentive can appear straightforward when described as a “120% deduction”, but the underlying analysis can be more complex.
Before claiming the additional deduction, businesses should consider:
- whether the activities constitute research or development under the applicable accounting framework;
- whether the expenditure has been correctly identified and allocated;
- whether expenditure is revenue or capital in nature;
- the timing of deductions for capitalised development expenditure;
- economic ownership of intellectual property arising from the R&D;
- whether the Cyprus IP Box has applied or may apply to the same intangible asset;
- whether the company has sufficient taxable profits or tax losses available; and
- whether the supporting records would withstand review by the Cyprus Tax Department.
An early review is particularly valuable for technology and IP-intensive businesses because decisions concerning accounting treatment, contractual ownership and project documentation are significantly easier to address while the project is ongoing.
How Evidentrust Can Help
Evidentrust Financial Services Ltd supports Cyprus technology companies, IP businesses and R&D-active companies with their tax compliance and advisory requirements, including:
- R&D deduction assessment — reviewing activities and expenditure to identify items requiring consideration under the Cyprus R&D provisions
- R&D documentation support — helping structure accounting and supporting records for a defensible tax position
- Accounting and tax treatment of development expenditure — assessing the treatment of expensed and capitalised development costs
- IP Box analysis — reviewing whether intellectual property and related income may qualify and assessing the interaction with the R&D deduction
- Corporate income tax compliance — incorporating the appropriate R&D deductions into the annual Cyprus tax computation and return
- Year-end tax review — identifying R&D and intellectual property tax matters before the financial year closes
If your business is investing in software development, technology, scientific research or other innovative activities, an early assessment can help determine whether the Cyprus R&D incentive is available and ensure that the appropriate supporting documentation is maintained.
To discuss whether your business may qualify for the Cyprus R&D super-deduction, contact Evidentrust for an initial discussion.
📧 info@evidentrust.com
📞 +357 25-327770
🌐 evidentrust.com/contact
This article is for general information only and should not be treated as tax, legal or professional advice. The information reflects our understanding of Cyprus tax law and practice as at August 2026. Tax legislation and administrative practice are subject to change, and the application of the rules depends on the specific facts and circumstances of each taxpayer. Professional advice should be obtained before taking or refraining from any action based on this article.
Published by Evidentrust Financial Services Ltd, Limassol, Cyprus. Regulated by ICPAC.
